- Home
- SPRU vs VYNE Comparison
SPRU vs VYNE Comparison
Compare SPRU & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRU
- VYNE
- Stock Information
- Founded
- SPRU 2008
- VYNE 2003
- Country
- SPRU United States
- VYNE United States
- Employees
- SPRU N/A
- VYNE N/A
- Industry
- SPRU Auto Parts:O.E.M.
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- SPRU Consumer Discretionary
- VYNE Health Care
- Exchange
- SPRU Nasdaq
- VYNE Nasdaq
- Market Cap
- SPRU 47.4M
- VYNE 41.9M
- IPO Year
- SPRU N/A
- VYNE 2018
- Fundamental
- Price
- SPRU $2.83
- VYNE $2.70
- Analyst Decision
- SPRU
- VYNE Strong Buy
- Analyst Count
- SPRU 0
- VYNE 2
- Target Price
- SPRU N/A
- VYNE $6.88
- AVG Volume (30 Days)
- SPRU 63.2K
- VYNE 153.7K
- Earning Date
- SPRU 03-13-2025
- VYNE 02-27-2025
- Dividend Yield
- SPRU N/A
- VYNE N/A
- EPS Growth
- SPRU N/A
- VYNE N/A
- EPS
- SPRU N/A
- VYNE N/A
- Revenue
- SPRU $77,582,000.00
- VYNE $493,000.00
- Revenue This Year
- SPRU $1.54
- VYNE $28.30
- Revenue Next Year
- SPRU $3.40
- VYNE N/A
- P/E Ratio
- SPRU N/A
- VYNE N/A
- Revenue Growth
- SPRU N/A
- VYNE 39.27
- 52 Week Low
- SPRU $2.17
- VYNE $1.57
- 52 Week High
- SPRU $4.89
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- SPRU 48.40
- VYNE 43.45
- Support Level
- SPRU $2.71
- VYNE $2.57
- Resistance Level
- SPRU $2.94
- VYNE $4.30
- Average True Range (ATR)
- SPRU 0.19
- VYNE 0.39
- MACD
- SPRU -0.04
- VYNE -0.11
- Stochastic Oscillator
- SPRU 23.08
- VYNE 7.51
About SPRU Spruce Power Holding Corporation
Spruce Power Holding Corp is a leading owner and operator of distributed solar energy assets across the United States (the U.S.), offering subscription-based services to approximately 75,000 home solar assets and customer contracts, making renewable energy more accessible to everyone. The Company's primary customers are homeowners and the Company's core solar service offerings generate revenues primarily through (i) the sale of electricity generated by its home solar energy systems to homeowners, (ii) third-party contracts to sell solar renewable energy credits (SRECs) generated by the solar energy systems for fixed prices and (iii) the servicing of those agreements for other institutional owners of home solar energy systems.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.